FCCC LOGO Faculty Publications
Plimack ER , Hudes GR
Selecting Targeted Therapies for Patients With Renal Cell Carcinoma
Journal of the National Comprehensive Cancer Network. 2011 Sep;9(9) :997-1007
PMID: WOS:000294584900005   
Back to previous list
Advanced renal cell carcinoma (RCC) is a heterogeneous disease with variable histology, biology, and response to treatment. In the past 5 years, 6 new agents have been approved for the treatment of RCC, and many more are in clinical development. With an ever-increasing number of treatment options, selecting among them for a particular patient can be a daunting task for clinicians. This article describes how treatment choice can be guided by the disease setting and histology, as well as patient characteristics, co-morbidities, and preference within the context of available data. Results from clinical trials are combined with practical considerations to make recommendations for first-line and subsequent treatment of patients with clear cell and non-clear cell RCC. These recommendations should supplement the current NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for the treatment of advanced RCC. (JNCCN 2011;9:997-1007)
Plimack, Elizabeth R. Hudes, Gary R. 67 Harborside press Cold spring harbor 816fu